Effectiveness of antiviral drug Kagocel<sup>®</sup> in complex treatment of viral and bacterial pneumonia in hospital

Abstract

Viruses that cause acute respiratory infections are currently widespread and are reported worldwide. Among the most dangerous among them are influenza viruses, with a difficult to predict course and the possibility of rapidly developing life-threatening complications that can lead to death.The purpose of the research work: to analyze the effectiveness and safety of the treatment of community-acquired viral-bacterial pneumonia in hospital patients using only antibacterial therapy as an etiotropic treatment in comparison with the combined use of antibacterial therapy and the antiviral drug Kagocel®.Materials and methods. An open, prospective comparative study was conducted (from January 1 to December 31, 2018) to study the effectiveness of monotherapy compared with combination therapy with the antiviral drug Kagocel® for 60 patients diagnosed with community-acquired pneumonia who were admitted during the period of an epidemic rise in the incidence of acute respiratory viral infections and influenza. All patients were treated in the infectious ward of the Regional Clinical Hospital No. 2, (Vladivostok, Russia). Patients were divided into 2 groups, 30 people each, comparable in age, gender and timing of admission to the hospital. The age of patients ranged from 18 to 65 years. The first group consisted of patients who received an antibacterial drug (control group) as an etiotropic therapy, the second group — those who received a combination of antibacterial and antiviral (Kagocel®) drugs (experimental group).Results. In the group of patients receiving both antibacterial and antiviral therapy with Kagocel®, there was a significant reduction in the duration of the febrile period and catarrhal manifestations compared with patients taking only antibiotics as part of etiotropic therapy. An analysis of the data showed that the use of Kagocel® in the treatment of viral-bacterial pneumonia significantly facilitates the patient’s condition during the illness, shortens the duration of the disease, reduces the duration of the main clinical symptoms of pneumonia, namely the duration of intoxication, catarrhal syndromes, and physical changes in the lungs.Conclusions. The use of the antiviral drug Kagocel® in the treatment of community-acquired viral-bacterial pneumonia leads to a more rapid relief of the main symptoms of the disease and reduces the duration of the disease. Good tolerance of the therapy, the absence of adverse reactions was noted.